SERNYSEPharmaceutical PreparationsFiscal year ends December 31

Serina Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.65−0.07 (-4.07%)

Close on Oct 19, 2026

Market cap: $27.04M
P/E (TTM): –
Dividend yield: –

Serina Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	3.06	3.67	7.62	0.65	0.58	0.53	2.35	6.71	7.38	0.26
Cash & Short-Term Investments	3.06	3.67	7.62	0.65	0.58	0.53	2.35	6.71	7.38	0.26
Receivables	–	–	0.06	0.00	0.03	0.33	0.36	0.13	0.11	–
Prepaid Expenses & Other	3.02	2.00	0	1.80	1.63	1.43	1.34	1.02	0.11	–
Other Current Assets	0.31	0.08	0	–	–	–	–	–	–	–
Total Current Assets	6.08	5.68	7.62	2.45	2.23	2.28	4.05	7.85	7.59	–
Property, Plant & Equipment	0.47	0.50	0.57	–	–	–	1.13	0.09	0.13	–
Gross Property, Plant & Equipment	0.99	1.10	0.96	–	–	–	–	0.25	0.27	–
Accumulated Depreciation	-0.53	-0.60	-0.39	–	–	-0.38	-0.55	-0.16	-0.15	–
Operating Lease Right-of-Use Assets	0.38	0.46	0.67	–	–	–	0.73	–	–	–
Intangible Assets	–	–	0	0.74	0.87	1.59	2.15	2.71	1.87	–
Total Assets	6.95	6.72	8.97	3.24	3.15	3.93	7.44	11	9.63	–
Accounts Payable	1.93	0.74	0.58	0.57	0.19	0.76	0.42	0.15	0.08	–
Accrued Expenses	1.21	1.43	0.58	0.27	0.37	–	–	–	–	–
Current Portion of Leases	0.20	0.19	0.21	–	–	–	0.43	–	–	–
Deferred Revenue (Current)	–	–	–	–	–	0.28	0.28	0.32	0.18	–
Other Current Liabilities	0.34	0.19	0.25	0.14	–	–	–	0.63	0.15	–
Total Current Liabilities	3.56	2.37	1.41	10	8.97	5.36	3.30	2.44	–	–
Long-Term Leases	0.20	0.27	0.46	–	–	–	–	–	–	–
Operating Lease Liabilities	0.38	0.46	0.68	–	–	–	0.43	–	–	–
Total Liabilities	6.99	6.22	4.86	21	15	9.32	4.83	2.44	1.31	–
Preferred Stock	4.94	0	0	–	–	–	–	–	–	–
Common Stock	0.00	0.00	0	0.00	0.00	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	59	45	0.88	99	94	92	88	81	74	–
Retained Earnings	-64	-44	-33	-116	-106	-97	-86	-74	-67	–
Comprehensive Income & Other	-0.01	0	–	–	–	0.14	0.07	0.00	0.07	–
Shareholders' Equity	-0.04	0.64	-32	-38	-12	-5.12	2.22	7.45	7.28	–
Noncontrolling Interest	0	-0.13	0	-0.10	-0.04	-0.28	0.40	0.78	1.04	–
Total Equity	-0.04	0.51	-32	-38	-12	-5.40	2.62	8.23	8.32	-22
Total Liabilities & Equity	6.95	6.72	8.97	3.24	3.15	3.93	7.44	11	9.63	–
Shares Outstanding(shares)	11	9.42	2.41	1.08	38	38	38	36	34	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -18478.5%
Net margin: -16288.5%
Return on equity, FY2025: -6351.7%

Financial strength

Current ratio: 6.65
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 612.0%

Valuation

P/E ratio: –
Price to sales: 207.96
Price to book: –
Dividend yield: –